Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to dual BRAF and MEK Inhibition in Melanoma Models

Emergence of clinical resistance to BRAF inhibitors, alone or in combination with MEK inhibitors, limits clinical responses in melanoma. Inhibiting HSP90 offers an approach to simultaneously interfere with multiple resistance mechanisms. Using the HSP90 inhibitor, AT13387, which is currently in clin...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Mol Cancer Ther
Autori principali: Smyth, Tomoko, Paraiso, Kim H T, Hearn, Keisha, Rodriguez-Lopez, Ana M, Munck, Joanne M, Haarberg, H Eirik, Sondak, Vernon K, Thompson, Neil T, Azab, Mohammad, Lyons, John F, Smalley, Keiran S M, Wallis, Nicola G
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2014
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4263034/
https://ncbi.nlm.nih.gov/pubmed/25349308
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-14-0452
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi